KRAS and non-small cell lung carcinoma: Here, we report in colon, pancreatic and NSCLC cell lines, the IC50 of target knockdown with AZD4785 (with unformulated delivery) differed dramatically, ranging from cell lines that had a robust knockdown, to those that had minimal or no knockdown of KRAS mRNA.